Zelda Therapeutics (ASX: ZLD)
Zelda Therapeutics (ASX: ZLD) is a biotech company active in the study and use of medicinal cannabis to treat a variety of ailments and medical conditions. www.zeldatherapeutics.com
Drawbacks of the TGA’s cannabis changes for listed pot stocks
Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator...
Zelira Therapeutics targets arterial disease and diabetic illnesses with medicinal cannabis
Medical cannabis company Zelira Therapeutics (ASX: ZLD) has committed to a binding five-year agreement with US-based company Cardiovascular Solu...
Zelira Therapeutics reveals more positive results from medical cannabis trial to treat insomnia
Zelira Therapeutics (ASX: ZLD) has announced its Phase 1b/2a medicinal cannabis trial to treat insomnia has met both its primary and secondary e...
Zelira Therapeutics meets primary endpoints for medical cannabis trial to treat insomnia
Biopharmaceutical company Zelira Therapeutics (ASX: ZLD) has announced positive results from a “first of its kind” phase 1b/2a trial using medic...
Health House Holdings to distribute Zelda Therapeutics’ medicinal cannabis throughout Australasia and UK
Zelda Therapeutics’ (ASX: ZLD) medicinal cannabis products will be distributed across Australasia and the United Kingdom under a new agreement w...
Zelda Therapeutics granted approval to trial medicinal cannabis in tackling the opioid epidemic
Bio-pharmaceutical company Zelda Therapeutics (ASX: ZLD) has taken a decisive step towards mitigating the effects of the growing opioid epidemic...
SUDA Pharmaceuticals and Zelda Therapeutics to develop novel medicinal cannabis oral spray
Drug delivery specialist company SUDA Pharmaceuticals (ASX: SUD) has unveiled a deal with Zelda Therapeutics (ASX: ZLD) in the form of a fully f...
Zelda Therapeutics commences its ‘pioneering’ insomnia trial using cannabis
Dual-listed biopharma company Zelda Therapeutics (ASX: ZLD) has kicked off its “pioneering” insomnia trial by dosing its first patient which it ...
IRB approval paves way for Zelda to begin cannabis trials in paediatric autism
Zelda Therapeutics (ASX: ZLD) has gained Institutional Review Board approval to trial its cannabinoid-based formulations on children suffering f...
Zelda Therapeutics broadens pancreatic cancer research as precursor to human trials
Zelda Therapeutics (ASX: ZLD) and West Australian-based Curtin University have broadened their pancreatic cancer research program to focus on in...
Zelda Therapeutics announces US stock market listing
Zelda Therapeutics (ASX: ZLD), an Australian biotech company focusing on medical cannabis, has announced that its shares have now been approved ...
Zelda Therapeutics teams up with US children’s hospital for medicinal cannabis autism study
Zelda Therapeutics (ASX: ZLD) has teamed up with a US children’s hospital to kick-off its observational study on treating paediatric autism with...
Zelda Therapeutics gets go ahead for medicinal cannabis trial to treat insomnia
In an Australian first, Zelda Therapeutics (ASX: ZLD) has been given the go ahead to begin its Australian medicinal cannabis trial for treating ...
Treating autism with medicinal cannabis returns positive results for Zelda Therapeutics
The Board of Zelda Therapeutics (ASX: ZLD) has sponsored an observation autism trial in Chile, demonstrating successful results for treating the...
Zelda Therapeutics enters strategic manufacturing and distribution agreement
Zelda Therapeutics (ASX: ZLD) has entered into a strategic manufacturing and distribution agreement with Knop Laboratories SA.
Key Highlights...
Zelda Therapeutics reports positive results in breast cancer study using cannabinoids
Zelda Therapeutics (ASX: ZLD) has reported positive results from its ongoing pre-clinical research into the use of cannabinoids as anti-cancer a...